10,178 results match your criteria Immune Thrombocytopenic Purpura


Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab.

Acta Clin Belg 2019 Apr 22:1-5. Epub 2019 Apr 22.

b Intensive Care Unit, Department of Internal Medicine , University Hospital Centre Zagreb , Zagreb , Croatia.

Objectives: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare autoimmune disorder characterized by auto-antibodies to Willebrand factor (vWF) cleaving enzyme (ADAMTS13), resulting in unusually large vWF multimers that lead to platelet aggregation, microthrombi formation and microangiopathic hemolytic anemia. Hemolysis in aTTP is mechanical; thus, direct antiglobulin test (Coombs test) is usually negative. Multiple autoimmune conditions and various auto-antibodies have been described in the context of chronic myelomonocytic leukemia (CMML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17843286.2019.1608395DOI Listing

Prognostic Factors for Immune Thrombocytopenic Purpura Remission after Laparoscopic Splenectomy: A Cohort Study.

Medicina (Kaunas) 2019 Apr 18;55(4). Epub 2019 Apr 18.

2nd Department of General Surgery, Jagiellonian University Medical College, Kopernika 21,31-501 Kraków, Poland.

Background And Objectives: Laparoscopic splenectomy (LS) has become the gold standard for patients with immune thrombocytopenic purpura (ITP). The total remission rate after splenectomy is 70%-90%, of which 66% is long-term. Despite this high response rate, some patients do not benefit from surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicina55040112DOI Listing

Psychiatric Disorders and Quality of Life in Egyptian Patients with Chronic Immune Thrombocytopenic Purpura: A Single Center Study.

Indian J Hematol Blood Transfus 2019 Apr 11;35(2):347-351. Epub 2018 Oct 11.

1Pediatrics Department, Faculty of Medicine, Mansoura University, Mansoura, 35516 Egypt.

The impact of chronic immune thrombocytopenic purpura (ITP) on the psychological health and quality of life is evident among children and adolescents. We aimed to describe psychological disorders and assess quality of life in children with chronic ITP and compared their results with their healthy peers. A cross-sectional comparative study was carried out in a tertiary care university-affiliated hospital during a period from November, 2015 till April, 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-1031-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439116PMC
April 2019
2 Reads

[Immune thrombocytopenic purpura].

Rev Prat 2019 Mar;69(3):290

Service d'odontologie, Groupe hospitalier La Pitié-Salpêtrière, Paris, France.

View Article

Download full-text PDF

Source
March 2019
1 Read

Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.

Int J Hematol 2019 Apr 10. Epub 2019 Apr 10.

Division of Hematology, Department of Medicine, University of Washington, 1959 NE Pacific St, Box 356330, Seattle, WA, 98195, USA.

A proportion of patients with immune thrombocytopenic purpura are refractory to multiple therapies including thrombopoietin-receptor agonists (TPO-RA). We report 10 patients who did not respond to a TPO-RA until the addition of a glucocorticoid. These patients were previously treated with a median of 6 therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02638-6DOI Listing
April 2019
1 Read

Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report.

Surg Case Rep 2019 Apr 10;5(1):56. Epub 2019 Apr 10.

Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.

Background: Patients with idiopathic thrombocytopenic purpura (ITP) have low platelet counts and an increased risk of complications. Therefore, these patients generally require high-dose immunoglobulin therapy and platelet transfusion. However, thrombopoietin receptor agonists (TPO-RAs) have recently become available for use in the preoperative treatment strategy for intractable ITP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0619-4DOI Listing
April 2019
1 Read

Mean Platelet Volume and Platelet Distribution Width Indicate that Platelets Remain Small for Most of Their Lifespans in Patients with Essential Thrombocythemia.

Clin Lab 2019 Apr;65(4)

Background: Platelets are large when young and immature and shrink as they age. The mean platelet volume (MPV) and platelet distribution width (PDW) reflect the volume and distribution of platelets, respectively. We compared the MPVs and PDWs of patients with immune thrombocytopenic purpura (ITP) or essential thrombocythemia (ET) to those of healthy individuals to test whether these values can reflect the pathomechanisms of these diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2018.180938DOI Listing
April 2019
1 Read

Involvement of Interferon-γ + 874A/T Polymorphism in the Pathogenesis of and Therapeutic Response to Immune Thrombocytopenia.

Lab Med 2019 Apr 7. Epub 2019 Apr 7.

Research Center of Thalassemia and Hemoglobinopathy, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Background: Immune thrombocytopenia (ITP) is an autoimmune disease characterized by symptoms of thrombocytopenia and bleeding due to production of autoantibodies against platelets. Recently, the occurrence of polymorphisms has been identified as one of the main causes of disease onset.

Methods: To conduct this study, we recruited 140 patients and control individuals with no history of platelet loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/labmed/lmz010DOI Listing
April 2019
1 Read

Disseminated tuberculosis with severe immune thrombocytopenia.

Respir Med Case Rep 2019 25;27:100812. Epub 2019 Feb 25.

Yashoda Hospitals, Malakpet, Hyderabad, Telangana, PIN-500036, India.

Immune thrombocytopenia is an autoimmune condition with increased platelet destruction. Immune thrombocytopenic purpura is an uncommon and rare manifestation of tuberculosis. A search of the literature available on TB-associated ITP identified only around 50 cases published between 1964 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2019.02.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430074PMC
February 2019
3 Reads

Acute myocardial infarction and renal dysfunction due to chronic extreme anemia (hemoglobin 2.5 g/dL) in immune thrombocytopenia.

Proc (Bayl Univ Med Cent) 2018 Oct 23;31(4):508-510. Epub 2018 Oct 23.

Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at HoustonHoustonTexas.

Immune thrombocytopenic purpura (ITP) is an acquired thrombocytopenia where autoantibodies are generated against platelet antigens. Primary ITP is often idiopathic, whereas secondary ITP has many potential causes, including drug induced, infection related (human immunodeficiency virus, hepatitis C), leukemias, or autoimmune such as systemic lupus erythematosus. ITP is a common cause of thrombocytopenia in asymptomatic individuals, where evidence of bleeding may be minor or absent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08998280.2018.1499317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413974PMC
October 2018
2 Reads

Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report.

J Immunother Cancer 2019 Apr 3;7(1):97. Epub 2019 Apr 3.

Department of Pathology, Sapporo Medical University, School of Medicine, South 1, West 17, Chuo-ku, Sapporo, Hokkaido, 060-8556, Japan.

Background: Immune checkpoint inhibitors (ICIs) have provided more options in the treatment of lung cancer. However, ICIs can cause several unfavorable reactions generally referred to as immune-related adverse effects.

Case Presentation: In this report, we present the case of a 52-year-old woman with successful regression of pleomorphic carcinoma of the lung following nivolumab therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0582-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448268PMC
April 2019
1 Read

Routine funduscopy in immune thrombocytopenic purpura-is it really necessary?

Eur J Pediatr 2019 Apr 2. Epub 2019 Apr 2.

Pediatric Emergency Medicine, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, 6 Weizman Street, 6423906, Tel-Aviv, Israel.

Immune thrombocytopenic purpura (ITP) is a common cause of symptomatic thrombocytopenia in children, most of whom present with cutaneous and mucosal bleeding. Complications, such as intracranial hemorrhage and occult hemorrhage from various sites, are rare, and retinal hemorrhage is exceptionally rare. Our institutional clinical practice guidelines for managing ITP in the pediatric emergency department (PED) include routine funduscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00431-019-03371-2DOI Listing
April 2019
2 Reads

Substantial improvement in immune thrombocytopenic purpura associated with T-cell/histiocyte-rich B-cell lymphoma treated with chemotherapy: A case report.

Mol Clin Oncol 2019 Apr 27;10(4):441-445. Epub 2019 Feb 27.

Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe City Hospital Organization, Kobe, Hyogo 650-0047, Japan.

Immune thrombocytopenic purpura (ITP) is characterized by antibody and immune platelet destruction, occasionally leading to life-threatening hemorrhage. ITP is a frequent complication of chronic lymphoid leukemia, but is rarely associated with diffuse large B-cell lymphoma (DLBCL). We herein describe a case of ITP associated with T-cell/histiocyte-rich B-cell lymphoma (T/HRBCL), which is a rare variant of DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2019.1816DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425504PMC
April 2019
6 Reads

[Efficacy and safety of recombinant human thrombopoietin in adult patients with primary immune thrombocytopenia during the perioperative period].

Zhonghua Xue Ye Xue Za Zhi 2019 Mar;40(3):191-194

Department of Hematology, Institute of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China.

To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) treatment for primary immune thrombocytopenia (ITP) patients during the perioperative period. Adult ITP patients who were refractory to first-line glucocorticoid therapy and underwent selective surgery were enrolled to be treated with rhTPO at the dosage of 1.5×10(4)U/d subcutaneously during the perioperative period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.03.005DOI Listing
March 2019
2 Reads

Bleeding Scales Applicable to Critically Ill Children: A Systematic Review.

Pediatr Crit Care Med 2019 Mar 28. Epub 2019 Mar 28.

Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA.

Objectives: To summarize current bleeding scales and their validation to assess applicability to bleeding in critically ill children.

Data Sources: We conducted electronic searches of Ovid MEDLINE, Ovid EMBASE, Cochrane Library, and Web of Science Core Collection databases from database inception to 2017.

Study Selection: Included studies contained a bleeding score, bleeding measurement tool, or clinical measurement of hemorrhage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PCC.0000000000001943DOI Listing
March 2019
3 Reads

Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy.

Cancer Cell Int 2019 15;19:59. Epub 2019 Mar 15.

Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, 325 Jing Wu Rd, Jinan, 250021 Shandong People's Republic of China.

Immune thrombocytopenic purpura (ITP) is a multifactorial autoimmune disease characterized by both increased platelet destruction and/or reduced platelet production. Even though they are detected in ≤ 50% of ITP patients, auto-antibodies play a pivotal role in the pathogenesis of ITP. Recent experimental and clinical observations have revealed abnormal autophagy in ITP patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0779-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419848PMC
March 2019
1 Read

Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.

Haematologica 2019 Mar 28. Epub 2019 Mar 28.

Justus Liebig University, Giessen, Germany;

Platelet autoantibody-induced platelet clearance represents a major pathomechanism in immune thrombocytopenia. Evidence for clinical differences between anti-glycoprotein IIb/IIIa and anti-glycoprotein Ib/IX mediated immune thrombocytopenia is currently accumulating. Glycoprotein V is a well characterized target antigen in Varicella-associated and drug-induced thrombocytopenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.211086DOI Listing
March 2019
1 Read

Immunophenotype anomalies predict the development of autoimmune cytopenia in 22q11.2 Deletion Syndrome.

J Allergy Clin Immunol Pract 2019 Mar 25. Epub 2019 Mar 25.

University Department of Pediatrics, Unit of Immune and Infectious Diseases, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Background: patients with 22q11.2DS may develop severe thrombocytopenic purpura (ITP) and hemolytic anemia (AIHA). There are no reliable predictors for the development of hematologic autoimmunity (HA) in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.03.014DOI Listing
March 2019
1 Read

Adipose-derived stem cells: Sources, potency, and implications for regenerative therapies.

Biomed Pharmacother 2019 Mar 25;114:108765. Epub 2019 Mar 25.

Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, PR China; Basic Medical Institute of Heilongjiang Medical Science Academy, PR China; Translational Medicine Center of Northern China, PR China. Electronic address:

Adipose-derived stem cells (ASCs) are a subset of mesenchymal stem cells (MSCs) that can be obtained easily from adipose tissues and possess many of the same regenerative properties as other MSCs. ASCs easily adhere to plastic culture flasks, expand in vitro, and have the capacity to differentiate into multiple cell lineages, offering the potential to repair, maintain, or enhance various tissues. Since human adipose tissue is ubiquitous and easily obtained in large quantities using a minimally invasive procedure, the use of autologous ASCs is promising for both regenerative medicine and organs damaged by injury and disease, leading to a rapidly increasing field of research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.108765DOI Listing
March 2019
1 Read

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura.

Br J Haematol 2019 Mar 28. Epub 2019 Mar 28.

Department of Haematology, UCLH NHS Foundation Trust, London, UK.

Immune thrombotic thrombocytopenic purpura (iTTP) is an acute, multisystem thrombotic microangiopathy mediated by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) autoantibodies. Immunosuppression with anti-CD20 therapy is the mainstay of treatment. MabThera's patent has now expired and biosimilars have been approved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15874DOI Listing
March 2019
2 Reads

A case for consideration by apheresis practitioners: Melanoma and PD-1 inhibitor treatment in a patient with multiple relapses of immune thrombotic thrombocytopenic purpura.

Transfus Apher Sci 2019 Mar 13. Epub 2019 Mar 13.

Departments of Medicine, St. Michael's Hospital and University of Toronto, Canada.

Thrombotic Thrombocytopenic Purpura (TTP) is a rare life-threatening disease caused by ADAMTS-13 deficiency. Up to forty percent of patients with TTP relapse, and most relapse within eight years of their first presentation. This case report describes a patient with an aggressive course of TTP who subsequently developed metastatic melanoma while receiving prophylactic rituximab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2019.03.001DOI Listing
March 2019
2 Reads

[TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA IN ADULTS: UPDATE].

Authors:
Dorit Blickstein

Harefuah 2019 Mar;158(3):196-199

Thrombosis and Hemostasis Unit, Institute of Hematology and Bone Marrow Transplantation, Rambam Health Care Center, Haifa.

Introduction: Primary immune thrombocytopenic purpura (ITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia (platelet count less than 100X109/L), caused by IgG autoantibodies which bind to platelets and megakaryocyte, T cell-mediated platelet destruction and impaired megakaryocytic function. Symptoms can manifest as petechiae, purpura, mucosal bleeding and rarely fatal intracranial hemorrhage, as well as reduced quality of life. A wide range of bleeding manifestations exists and it is impossible to tell who will bleed, when and where. Read More

View Article

Download full-text PDF

Source
March 2019
6 Reads

Post-Transfusion Purpura Mimicking Idiopathic Thrombocytopenic Purpura: A Case Report.

Lab Med 2019 Mar 27. Epub 2019 Mar 27.

Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.

The main clinical distinction between post-transfusion purpura (PTP) and idiopathic thrombocytopenic purpura (ITP) is the sudden development of severe thrombocytopenia in the days after transfusion. Herein, we report the case of a 53-year-old Caucasian woman who developed multiple myeloma (MM) after peripheral blood-stem-cell transplant (PBSCT), along with severe thrombocytopenia (with a nadir of 1 × 109/L); she also experienced severe adverse events after each platelet transfusion, including the first one. These reactions were absent with any other transfused blood products. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/labmed/lmz004DOI Listing
March 2019
1 Read

Successful use of TNFα blockade in a severe case of idiopathic non-granulomatous ulcerative jejunoileitis associated with thrombotic thrombocytopenic purpura.

BMJ Open Gastroenterol 2019 8;6(1):e000252. Epub 2019 Feb 8.

Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

We describe the case of 50-year-old female patient who presented with severe gastrointestinal symptoms and progressive weight loss of unknown origin. Shortly after admission, she developed an acute flare of thrombotic thrombocytopaenic purpura (TTP) that had to be treated by plasma exchange therapy and rituximab administration. While the signs of TTP subsided, the gastrointestinal symptoms worsened with abdominal cramps, massive gastric retention, malnourishment and a stenosis due to extensive inflammation and wall thickening of the small bowel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjgast-2018-000252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398868PMC
February 2019
1 Read

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura.

Exp Ther Med 2019 Mar 23;17(3):2137-2142. Epub 2019 Jan 23.

Ward Pharmacy, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China.

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura (ITP) were investigated. We retrospectively analyzed 249 patients with refractory ITP who were admitted to Qingdao Hiser Medical Group between March 2013 and March 2017. Curative effects of patients treated with rituximab, cyclophosphamide, and combination therapy were observed and the changes of platelet count, PA IgG, and lymphocyte CD20 before and after treatment, as well as the incidence of adverse reactions after treatment, were compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395969PMC
March 2019
2 Reads

Etiology and Outcomes of Thrombotic Microangiopathies.

Clin J Am Soc Nephrol 2019 Apr 12;14(4):557-566. Epub 2019 Mar 12.

Service de Néphrologie-hypertension, Dialyses, Transplantation Rénale, Hôpital Bretonneau et hôpital Clocheville,

Background And Objectives: Thrombotic microangiopathies constitute a diagnostic and therapeutic challenge. Secondary thrombotic microangiopathies are less characterized than primary thrombotic microangiopathies (thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome). The relative frequencies and outcomes of secondary and primary thrombotic microangiopathies are unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2215/CJN.11470918DOI Listing
April 2019
3 Reads

Immune thrombocytopenic purpura in a patient with disseminated tuberculosis: An unusual presentation.

Int J Mycobacteriol 2019 Jan-Mar;8(1):107-109

Department of Internal Medicine, Sri Balaji Action Medical Institute, New Delhi, India.

Pulmonary tuberculosis can have a wide variety of presentations including hematological manifestations. We report a case of a young male patient who presented with complaints of generalized petechiae, gum bleeding, systemic lymphadenopathy, and severe thrombocytopenia. His bone marrow revealed normal megakaryocytes, and in the absence of hepatosplenomegaly, a diagnosis of immune thrombocytopenic purpura (ITP) was made. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijmy.ijmy_169_18DOI Listing
March 2019
2 Reads

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

Haematologica 2019 Mar 7. Epub 2019 Mar 7.

Amgen Inc., Thousand Oaks, CA, USA.

Children with immune thrombocytopenia ≥6 months completing a romiplostim study received weekly subcutaneous romiplostim (1-10 mg/kg targeting platelet counts of 50-200x10/L) in this extension to examine romiplostim's long-term safety and efficacy. Sixty-five children received romiplostim for a median (range) of 2.6 (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.202283DOI Listing
March 2019
1 Read

Erratum.

Authors:

Acta Med Okayama 2019 02;73(1):91

Erratum to "High-dose Dexamethasone Therapy as the Initial Treatment for Idiopathic Thrombocytopenic Purpura: Protocol for a Multicenter, Open-label, Single Arm Trial" Vol.72, No.2, pp197-201. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18926/AMO/56465DOI Listing
February 2019
1 Read

Hematologic Complications of Immune Checkpoint Inhibitors.

Oncologist 2019 Feb 28. Epub 2019 Feb 28.

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Immune checkpoint inhibitors have improved outcomes for patients with numerous hematological and solid cancers. Hematologic toxicities have been described, but the spectrum, timing, and clinical presentation of these complications are not well understood. We used the World Health Organization's pharmacovigilance database of individual-case-safety-reports (ICSRs) of adverse drug reactions, VigiBase, to identify cases of hematologic toxicities complicating immune checkpoint inhibitor therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0574DOI Listing
February 2019
3 Reads

Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicenter study.

Intern Med J 2019 Feb 28. Epub 2019 Feb 28.

Department of Internal Medicine, Reference center of autoimmune cytopenias, University Hospital Henri-Mondor, APHP, UPEC, Créteil, France.

Background: increased risk of thrombosis has been reported in immune thrombocytopenic purpura (ITP), but the characteristics, risk factors of occurrence, recurrence and management of venous thromboembolic events (VTEs) have been poorly investigated.

Aims: to describe VTE and ITP characteristics, distribution of VTE risk factors and their impact on VTE features and recurrence.

Methods: retrospective study of patients with ITP and VTE registered in databases of 3 reference French centers of ITP RESULTS: Among 49 patients, 66 VTEs were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14269DOI Listing
February 2019
3 Reads

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.

Platelets 2019 Feb 27:1-8. Epub 2019 Feb 27.

a Department of Pediatrics , Fujian Medical University Union Hospital , Fuzhou , Fujian Province , China.

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder presenting with low platelet count <100 × 10/L. The condition affects both adults and children. Thrombopoietin receptor agonists (TPO-RAs) are second-line of therapy that includes Romiplostim and Eltrombopag, which stimulate the production of normally functioning platelets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09537104.2019.1572873DOI Listing
February 2019
1 Read

Immune thrombocytopenic purpura.

J Community Hosp Intern Med Perspect 2019 11;9(1):59-61. Epub 2019 Feb 11.

Department of Medicine, Unity Hospital, Rochester Regional Health, Rochester, NY, USA.

Immune thrombocytopenic purpura (ITP) is a bleeding disorder characterized by isolated thrombocytopenia (platelet count <150,000 u/L), which is not associated with a systemic illness. ITP is reported in approximately 2 per 100,000 adults. The mean age of diagnosis is 50 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/20009666.2019.1565884DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374974PMC
February 2019
4 Reads

Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report.

BMC Musculoskelet Disord 2019 Feb 19;20(1):88. Epub 2019 Feb 19.

Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.

Background: The incidence of bilateral corticosteroid-induced osteonecrosis of the femoral head (ONFH) is high. Although the precise mechanism of corticosteroid-induced ONFH development is unclear, hepatic enzyme abnormalities such as low activity of hepatic cytochrome P450 3A could be one cause. Herein, we report the case of a patient who developed ONFH in the contralateral hip after the dose of corticosteroids for idiopathic thrombocytopenic purpura was increased. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12891-019-2468-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381694PMC
February 2019
2 Reads

Juvenile polyautoimmunity in a rheumatology setting.

Autoimmun Rev 2019 Apr 14;18(4):369-381. Epub 2019 Feb 14.

Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.. Electronic address:

Overt polyautoimmunity (PolyA) corresponds to the presence of more than one well-defined autoimmune disease (AD) manifested clinically in a single patient. The current study aimed to describe the main characteristics of juvenile PolyA in a pediatric rheumatology setting and analyze the chronological aspects, index cases, familial autoimmunity, and clustering pattern. This was a cross-sectional and multicenter study in which 313 children with overt PolyA were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.006DOI Listing
April 2019
2 Reads
7.933 Impact Factor

Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.

Eur J Haematol 2019 May 7;102(5):416-423. Epub 2019 Mar 7.

Barts and The London School of Medicine and Dentistry, London, UK.

Background: Romiplostim is a thrombopoietin-mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts and romiplostim usage in UK clinical practice.

Methods: This was a retrospective cohort study of patients in the UKITP Registry who received romiplostim between October 2009 and January 2015, including data up to 6 months before romiplostim initiation through follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13221DOI Listing
May 2019
2 Reads

Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Curr Opin Rheumatol 2019 May;31(3):231-240

Division of Rheumatology, Department of Internal Medicine, University of Michigan.

Purpose Of Review: Although antiphospholipid syndrome (APS) is best known for conveying increased risk of thrombotic events and pregnancy morbidity, thrombocytopenia is also recognized as a common association. In this review, we will explore the relationship between thrombocytopenia and APS, highlighting our evolving understanding - and persistent knowledge gaps - through clinically oriented questions and answers.

Recent Findings: A history of thrombocytopenia likely portends a more severe APS phenotype (including increased risk of thrombosis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000595DOI Listing
May 2019
2 Reads

[Role of Th9, Th17, Treg Cells levels and IL-9, IL-17 and TGF-β Expression in Peripheral Blood of Patients with ITP in Pathogenesis of ITP].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):180-184

Department of Laboratorial Medicine.The First People's Hospital of Jingzhou in Hubei Province, Jingzhou 434000, Hubei Province, China.

Objective: To detect the levels of Treg, Th17, Th9 cells and expression of transforming growth factor-β (TGF-β), interleukin-17 (IL-17) and interleukin-9 (IL-9) in peripheral blood of patients with immune thrombocytopenia (ITP) and to explore its role in the pathogenesis of ITP.

Methods: Fifty-four patients with ITP (ITP group) and 40 healthy volunteers (control group) were selected in our hospital. The of Treg, Th17 and Th9 cells in peripheral blood of 2 groups were measured by flow cytometry, and the expression of cytokines, such as TGF-β, IL-17 and IL-9 in the peripheral blood of 2 groups were detected by enzyme linked immunosorbent assay (ELISA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.029DOI Listing
February 2019

A Case of Pregnancy Complicated with Evans Syndrome with Sequential Development of Autoimmune Warm Antibody Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura.

Case Rep Obstet Gynecol 2019 14;2019:2093612. Epub 2019 Jan 14.

Department of Obstetrics and Gynecology, Toyooka Public Hospital, 1094, Tobera, Toyooka City, Hyogo 6680065, Japan.

The simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP) is known as Evans syndrome. We experienced a case of Evans syndrome that developed AIHA during pregnancy and ITP long after delivery. The patient was a 35-year-old pregnant woman (gravida 2, para 1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/2093612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348819PMC
January 2019
2 Reads

Mean Platelet Volume, Platelet Distribution Width, and Platelet Count, in Connection with Immune Thrombocytopenic Purpura and Essential Thrombocytopenia.

Lab Med 2019 Feb 6. Epub 2019 Feb 6.

Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea.

Objective: To examine the kinetic characteristics of platelet (PLT) destruction and thrombopoiesis by using mean platelet volume (MPV) and platelet distribution width (PDW).

Methods: Using the ADVIA2120i instrument, we measured PLT counts, MPV, and PDW in 153 healthy individuals, 35 patients with immune thrombocytopenic purpura (ITP), and 48 patients with essential thrombocytopenia (ET).

Results: In the ITP group, the MPV and PDW were higher than those values in healthy individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/labmed/lmy082DOI Listing
February 2019
3 Reads
0.489 Impact Factor

[Successful management of primary immune thrombocytopenia with romiplostim during open heart surgery in a hemodialysis patient].

Rinsho Ketsueki 2019;60(1):28-32

Department of Hematology, Faculty of Medicine, University of Tsukuba.

A 66-year-old male undergoing maintenance hemodialysis presented with mild thrombocytopenia. He also had aortic valve stenosis and required aortic valve replacement. In addition, he required anticoagulation therapy with warfarin because of chronic subclavian artery occlusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.28DOI Listing
January 2019
4 Reads

CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID.

Front Immunol 2018 22;9:3135. Epub 2019 Jan 22.

Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia.

Common variable immunodeficiency disorder (CVID) is one of the most frequent inborn errors of immunity, increased occurrence of malignancies, particularly lymphomas, and gastric cancers, has long been noted among CVID patients. Multifactorial etiology, including immune dysregulation, infections, chronic inflammation, or genetic background, is suggested to contribute to tumor development. Here, we present the results of the first Czech nationwide study focused on epidemiology, immunology and genetic background in a cohort of CVID patients who also developed tumors The cohort consisted of 295 CVID patients followed for 3,070 patient/years. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.03135
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.03135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349737PMC
January 2019
10 Reads

Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.

Blood Coagul Fibrinolysis 2019 Mar;30(2):71-74

Department of Paediatric, Yantai Yu Huang Ding Hospital Affiliated to Qingdao University Medical College, Yantai, Shandong, China.

: The treatment of refractory primary immune thrombocytopenia (RITP) remains challenging because of the lack of well tolerated and effective drugs. Eltrombopag is approved for pediatric patients, who were aged at least 1 year, having chronic primary immune thrombocytopenia in 2015. Eltrombopag can quickly promote platelets and be conveniently used, thereby providing a new treatment option for patients with immune thrombocytopenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MBC.0000000000000794DOI Listing
March 2019
1 Read
1.380 Impact Factor

Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

Blood and Marrow Transplant Center, Florida Hospital Cancer Institute, Orlando, Florida. Electronic address:

Thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-SCT) can pose significant problems in management of patients. Eltrombopag is a small-molecule thrombopoietin receptor agonist that has been approved for use in immune thrombocytopenic purpura and aplastic anemia; but its use after allo-SCT is limited. Between 2014 and 2017, we treated 13 patients with eltrombopag for poor platelet engraftment without evidence of relapse at the time of initiation, including 6 patients with primary platelet engraftment failure and 7 with secondary platelet engraftment failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.027DOI Listing
January 2019
3 Reads
3.404 Impact Factor

Long-lasting response to afatinib that persisted after treatment discontinuation in a case of -mutated lung adenocarcinoma.

BMJ Case Rep 2019 Jan 31;12(1). Epub 2019 Jan 31.

Division of Respirology, Department of Internal Medicine, The Jikei University Hospital, Tokyo, Japan.

It is unknown whether tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) can be discontinued in patients in whom -mutated lung cancer has well stabilised. We present a case of a 73-year-old Japanese woman with no history of smoking. Right pulmonary lower lobectomy, lymph node dissection and segmental resection of the right middle lobe were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-227383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357919PMC
January 2019
2 Reads

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.

Ter Arkh 2018 Aug;90(7):70-76

National Medical Research Center of Children's Hematology, Oncology and Immunology named after Dmitry Rogachev of the Russian Federation Ministry of Health, Moscow, Russia.

Aim: To analyze the long-term efficacy and safety of ATR in adult patients with primary resistant ITP in real-world clinical practice.

Materials And Methods: The article contains long-term results analysis of ATR application under real clinical practice conditions in 138 patients (40 men and 98 women) whose median age at the beginning of therapy was 59 (18-86) years. Two ATR medicines-romiplostim (100 patients) and eltrombopag (38 patients) were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh201890770-76DOI Listing
August 2018
3 Reads